;PMID: 7606813
;source_file_939.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..45] = [t:0..45]
;1)sentence:[e:51..177] = [t:51..177]
;2)section:[e:181..289] = [t:181..289]
;3)section:[e:293..418] = [t:293..418]
;4)sentence:[e:422..617] = [t:422..617]
;5)sentence:[e:618..734] = [t:618..734]
;6)sentence:[e:736..873] = [t:736..873]
;7)sentence:[e:874..1083] = [t:874..1083]
;8)sentence:[e:1084..1178] = [t:1084..1178]
;9)sentence:[e:1179..1379] = [t:1179..1379]
;10)sentence:[e:1380..1429] = [t:1380..1429]
;11)sentence:[e:1430..1505] = [t:1430..1505]
;12)sentence:[e:1506..1607] = [t:1506..1607]
;13)sentence:[e:1609..1744] = [t:1609..1744]
;14)sentence:[e:1745..1943] = [t:1745..1943]
;15)sentence:[e:1944..2065] = [t:1944..2065]
;16)sentence:[e:2066..2184] = [t:2066..2184]
;17)sentence:[e:2185..2426] = [t:2185..2426]
;18)sentence:[e:2427..2643] = [t:2427..2643]
;19)sentence:[e:2644..2715] = [t:2644..2715]
;20)sentence:[e:2716..2809] = [t:2716..2809]
;21)sentence:[e:2810..2939] = [t:2810..2939]
;22)section:[e:2943..2987] = [t:2943..2987]

;section 0 Span:0..45
;Chem Biol Interact. 1995 Jul 14;97(2):149-68.
(SEC
  (FRAG (NNP:[0..4] Chem) (NNP:[5..9] Biol) (NNP:[10..18] Interact)
        (.:[18..19] .) (CD:[20..24] 1995) (IN:[25..28] Jul)
        (CD:[29..35] 14;97-LRB-) (CD:[35..36] 2) (-RRB-:[36..37] -RRB-)
        (CD:[37..41] :149) (::[41..42] -) (CD:[42..44] 68) (.:[44..45] .)))

;sentence 1 Span:51..177
;The cytotoxicity of mitomycin C and adriamycin in genetically engineered V79 
;cell lines and freshly isolated rat hepatocytes.
;[71..82]:substance:"mitomycin C"
;[87..97]:substance:"adriamycin"
(SENT
  (NP-HLN
    (NP (DT:[51..54] The) (NN:[55..67] cytotoxicity))
    (PP (IN:[68..70] of)
      (NP
        (NP (NN:[71..80] mitomycin) (NN:[81..82] C))
        (CC:[83..86] and)
        (NP (NN:[87..97] adriamycin))))
    (PP-LOC (IN:[98..100] in)
      (NP
        (NP
          (ADJP (RB:[101..112] genetically) (VBN:[113..123] engineered))
          (NN:[124..127] V79) (NN:[129..133] cell) (NNS:[134..139] lines))
        (CC:[140..143] and)
        (NP
          (ADJP (RB:[144..151] freshly) (VBN:[152..160] isolated))
          (NN:[161..164] rat) (NNS:[165..176] hepatocytes))))
    (.:[176..177] .)))

;section 2 Span:181..289
;Goeptar AR, te Koppele JM, Glatt HR, Groot EJ, Seidel A, Barrenscheen M,
;Wolfel  C, Doehmer J, Vermeulen NP.
(SEC
  (FRAG (NNP:[181..188] Goeptar) (NNP:[189..191] AR) (,:[191..192] ,)
        (NN:[193..195] te) (NNP:[196..203] Koppele) (NNP:[204..206] JM)
        (,:[206..207] ,) (NNP:[208..213] Glatt) (NN:[214..216] HR)
        (,:[216..217] ,) (NNP:[218..223] Groot) (NNP:[224..226] EJ)
        (,:[226..227] ,) (NNP:[228..234] Seidel) (NNP:[235..236] A)
        (,:[236..237] ,) (NNP:[238..250] Barrenscheen) (NNP:[251..253] M,)
        (NNP:[254..260] Wolfel) (NNP:[262..263] C) (,:[263..264] ,)
        (NNP:[265..272] Doehmer) (NNP:[273..275] J,) (NNP:[276..285] Vermeulen)
        (NNP:[286..288] NP) (.:[288..289] .)))

;section 3 Span:293..418
;Leiden/Amsterdam Center for Drug Research, Division of Molecular Toxicology, 
;Vrije Universiteit, Amsterdam, The Netherlands.
(SEC
  (FRAG (NN:[293..299] Leiden) (SYM:[299..300] /) (NN:[300..309] Amsterdam)
        (NNP:[310..316] Center) (IN:[317..320] for) (NNP:[321..325] Drug)
        (NNP:[326..334] Research) (,:[334..335] ,) (NNP:[336..344] Division)
        (IN:[345..347] of) (NNP:[348..357] Molecular)
        (NNP:[358..368] Toxicology) (,:[368..369] ,) (NNP:[371..376] Vrije)
        (NNP:[377..389] Universiteit) (,:[389..390] ,)
        (NNP:[391..400] Amsterdam) (,:[400..401] ,) (DT:[402..405] The)
        (NNP:[406..417] Netherlands) (.:[417..418] .)))

;sentence 4 Span:422..617
;The objective of the present study was to investigate the cytotoxicity of 
;Adriamycin (ADR) and mitomycin C (MMC) in tumor and non-tumor cells with
;respect  to the role of cytochrome P450 (P450).
;[497..507]:substance:"Adriamycin"
;[509..512]:substance:"ADR"
;[518..529]:substance:"mitomycin C"
;[531..534]:substance:"MMC"
;[594..609]:cyp450:"cytochrome P450"
;[611..615]:cyp450:"P450"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[422..425] The) (NN:[426..435] objective))
      (PP (IN:[436..438] of)
        (NP (DT:[439..442] the) (JJ:[443..450] present) (NN:[451..456] study))))
    (VP (VBD:[457..460] was)
      (S-PRP-PRD
        (NP-SBJ (-NONE-:[460..460] *))
        (VP (TO:[461..463] to)
          (VP (VB:[464..475] investigate)
            (NP
              (NP (DT:[476..479] the) (NN:[480..492] cytotoxicity))
              (NP (IN:[493..495] of)
                (NP
                  (NP
                    (NP (NNP:[497..507] Adriamycin))
                    (NP (-LRB-:[508..509] -LRB-) (NN:[509..512] ADR)
                        (-RRB-:[512..513] -RRB-)))
                  (CC:[514..517] and)
                  (NP
                    (NP (NN:[518..527] mitomycin) (NN:[528..529] C))
                    (NP (-LRB-:[530..531] -LRB-) (NN:[531..534] MMC)
                        (-RRB-:[534..535] -RRB-))))))
            (PP-LOC (IN:[536..538] in)
              (NP
                (NP (NN:[539..544] tumor)
                  (NML-1 (-NONE-:[544..544] *P*)))
                (CC:[545..548] and)
                (NP
                  (NML (AFX:[549..552] non) (HYPH:[552..553] -)
                       (NN:[553..558] tumor))
                  (NML-1 (NNS:[559..564] cells)))))
            (PP (IN:[565..569] with)
              (NP
                (NP (NN:[570..577] respect))
                (PP (TO:[579..581] to)
                  (NP
                    (NP (DT:[582..585] the) (NN:[586..590] role))
                    (PP (IN:[591..593] of)
                      (NP
                        (NP (NN:[594..604] cytochrome) (NN:[605..609] P450))
                        (NP (-LRB-:[610..611] -LRB-) (NN:[611..615] P450)
                            (-RRB-:[615..616] -RRB-))))))))))))
    (.:[616..617] .)))

;sentence 5 Span:618..734
;Therefore, genetically engineered V79  Chinese hamster fibroblasts expressing
;only single enzymes of P450 were used.
;[708..715]:cyp450:"enzymes"
;[719..723]:cyp450:"P450"
(SENT
  (S
    (ADVP (RB:[618..627] Therefore))
    (,:[627..628] ,)
    (NP-SBJ-1
      (NP
        (ADJP (RB:[629..640] genetically) (VBN:[641..651] engineered))
        (NN:[652..655] V79)
        (NML (JJ:[657..664] Chinese) (NN:[665..672] hamster))
        (NNS:[673..684] fibroblasts))
      (VP (VBG:[685..695] expressing)
        (ADVP (RB:[696..700] only))
        (NP
          (NP (JJ:[701..707] single) (NNS:[708..715] enzymes))
          (PP (IN:[716..718] of)
            (NP (NN:[719..723] P450))))))
    (VP (VBD:[724..728] were)
      (VP (VBN:[729..733] used)
        (NP-1 (-NONE-:[733..733] *))))
    (.:[733..734] .)))

;sentence 6 Span:736..873
;SD1 and XEM2 cells expressed rat P450IIB1 and P450IA1, respectively, whereas
;the  V79 parental cells contained no detectable P450 levels.
;[769..777]:cyp450:"P450IIB1"
;[782..789]:cyp450:"P450IA1"
;[861..865]:cyp450:"P450"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[736..739] SD1)
        (NML-2 (-NONE-:[739..739] *P*)))
      (CC:[740..743] and)
      (NP (NN:[744..748] XEM2)
        (NML-2 (NNS:[749..754] cells))))
    (VP (VBD:[755..764] expressed)
      (NP
        (NP
          (NML-1 (NN:[765..768] rat))
          (NN:[769..777] P450IIB1))
        (CC:[778..781] and)
        (NP
          (NML-1 (-NONE-:[781..781] *P*))
          (NN:[782..789] P450IA1)))
      (,:[789..790] ,)
      (ADVP (RB:[791..803] respectively))
      (,:[803..804] ,)
      (SBAR-ADV (IN:[805..812] whereas)
        (S
          (NP-SBJ (DT:[813..816] the) (NN:[818..821] V79)
                  (JJ:[822..830] parental) (NNS:[831..836] cells))
          (VP (VBD:[837..846] contained)
            (NP (DT:[847..849] no) (JJ:[850..860] detectable)
                (NN:[861..865] P450) (NNS:[866..872] levels))))))
    (.:[872..873] .)))

;sentence 7 Span:874..1083
;The cytotoxicity of ADR  and MMC in the V79 cell system was compared with
;that in freshly isolated  hepatocytes from phenobarbital (PB-hepatocytes)-
;and beta-naphthoflavone (beta  NF-hepatocytes)-induced rats.
;[894..897]:substance:"ADR"
;[903..906]:substance:"MMC"
;[991..1004]:substance:"phenobarbital"
;[1006..1008]:substance:"PB"
;[1027..1046]:substance:"beta-naphthoflavone"
;[1048..1056]:substance:"beta  NF"
(SENT
  (S
    (NP-SBJ-3
      (NP (DT:[874..877] The) (NN:[878..890] cytotoxicity))
      (PP (IN:[891..893] of)
        (NP (NN:[894..897] ADR) (CC:[899..902] and) (NN:[903..906] MMC)))
      (PP-LOC (IN:[907..909] in)
        (NP (DT:[910..913] the) (NN:[914..917] V79) (NN:[918..922] cell)
            (NN:[923..929] system))))
    (VP (VBD:[930..933] was)
      (VP (VBN:[934..942] compared)
        (NP-3 (-NONE-:[942..942] *))
        (PP-CLR (IN:[943..947] with)
          (NP
            (NP (DT:[948..952] that))
            (PP-LOC (IN:[953..955] in)
              (NP
                (NP
                  (ADJP (RB:[956..963] freshly) (VBN:[964..972] isolated))
                  (NNS:[974..985] hepatocytes))
                (PP (IN:[986..990] from)
                  (NP
                    (NP
                      (ADJP
                        (NML (NN:[991..1004] phenobarbital)
                          (PRN (-LRB-:[1005..1006] -LRB-)
                            (NP (NN:[1006..1008] PB) (HYPH:[1008..1009] -)
                                (NNS:[1009..1020] hepatocytes))
                            (-RRB-:[1020..1021] -RRB-)))
                        (HYPH:[1021..1022] -)
                        (ADJP-1 (-NONE-:[1022..1022] *P*)))
                      (NML-2 (-NONE-:[1022..1022] *P*)))
                    (CC:[1023..1026] and)
                    (NP
                      (ADJP
                        (NML (NN:[1027..1046] beta-naphthoflavone)
                          (PRN (-LRB-:[1047..1048] -LRB-)
                            (NP
                              (NML (SYM:[1048..1052] beta) (NN:[1054..1056] NF))
                              (HYPH:[1056..1057] -)
                               (NNS:[1057..1068] hepatocytes))
                            (-RRB-:[1068..1069] -RRB-)))
                        (HYPH:[1069..1070] -)
                        (ADJP-1 (VBN:[1070..1077] induced)))
                      (NML-2 (NNS:[1078..1082] rats)))))))))))
    (.:[1082..1083] .)))

;sentence 8 Span:1084..1178
;Following 24 h of exposure to ADR equal  cytotoxicity was observed in V79,
;SD1 and XEM2 cells.
;[1094..1096]:quantitative-value:"24"
;[1097..1098]:quantitative-units:"h"
;[1114..1117]:substance:"ADR"
(SENT
  (S
    (PP (VBG:[1084..1093] Following)
      (NP
        (NP (CD:[1094..1096] 24) (NN:[1097..1098] h))
        (PP (IN:[1099..1101] of)
          (NP
            (NP (NN:[1102..1110] exposure))
            (PP (TO:[1111..1113] to)
              (NP (NN:[1114..1117] ADR)))))))
    (NP-SBJ-2 (JJ:[1118..1123] equal) (NN:[1125..1137] cytotoxicity))
    (VP (VBD:[1138..1141] was)
      (VP (VBN:[1142..1150] observed)
        (NP-2 (-NONE-:[1150..1150] *))
        (PP-LOC (IN:[1151..1153] in)
          (NP
            (NP (NN:[1154..1157] V79)
              (NML-1 (-NONE-:[1157..1157] *P*)))
            (,:[1157..1158] ,)
            (NP (NN:[1159..1162] SD1)
              (NML-1 (-NONE-:[1162..1162] *P*)))
            (CC:[1163..1166] and)
            (NP (NN:[1167..1171] XEM2)
              (NML-1 (NNS:[1172..1177] cells)))))))
    (.:[1177..1178] .)))

;sentence 9 Span:1179..1379
;Addition of metyrapone  (MP, an inhibitor of P450IIB1) and
;alpha-naphthoflavone (alpha NF, an inhibitor  of P450IA1) had no effect on
;the ADR-induced cytotoxicity in SD1 and XEM2 cells,  respectively.
;[1191..1201]:substance:"metyrapone"
;[1204..1206]:substance:"MP"
;[1211..1220]:substance:"inhibitor"
;[1224..1232]:cyp450:"P450IIB1"
;[1238..1258]:substance:"alpha-naphthoflavone"
;[1260..1268]:substance:"alpha NF"
;[1273..1282]:substance:"inhibitor"
;[1287..1294]:cyp450:"P450IA1"
;[1317..1320]:substance:"ADR"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1179..1187] Addition))
      (PP (IN:[1188..1190] of)
        (NP
          (NP
            (NP (NN:[1191..1201] metyrapone))
            (NP (-LRB-:[1203..1204] -LRB-)
              (NP (NN:[1204..1206] MP))
              (,:[1206..1207] ,)
              (NP
                (NP (DT:[1208..1210] an) (NN:[1211..1220] inhibitor))
                (PP (IN:[1221..1223] of)
                  (NP (NN:[1224..1232] P450IIB1))))
              (-RRB-:[1232..1233] -RRB-)))
          (CC:[1234..1237] and)
          (NP
            (NP (NN:[1238..1258] alpha-naphthoflavone))
            (NP (-LRB-:[1259..1260] -LRB-)
              (NP (SYM:[1260..1265] alpha) (NN:[1266..1268] NF))
              (,:[1268..1269] ,)
              (NP
                (NP (DT:[1270..1272] an) (NN:[1273..1282] inhibitor))
                (PP (IN:[1284..1286] of)
                  (NP (NN:[1287..1294] P450IA1))))
              (-RRB-:[1294..1295] -RRB-))))))
    (VP (VBD:[1296..1299] had)
      (NP
        (NP (DT:[1300..1302] no) (NN:[1303..1309] effect))
        (PP (IN:[1310..1312] on)
          (NP (DT:[1313..1316] the)
            (ADJP (NN:[1317..1320] ADR) (HYPH:[1320..1321] -)
                  (VBN:[1321..1328] induced))
            (NN:[1329..1341] cytotoxicity))))
      (PP-LOC (IN:[1342..1344] in)
        (NP
          (NP (NN:[1345..1348] SD1)
            (NML-1 (-NONE-:[1348..1348] *P*)))
          (CC:[1349..1352] and)
          (NP (NN:[1353..1357] XEM2)
            (NML-1 (NNS:[1358..1363] cells))))
        (,:[1363..1364] ,)
        (ADVP (RB:[1366..1378] respectively))))
    (.:[1378..1379] .)))

;sentence 10 Span:1380..1429
;Likewise, MMC was equitoxic in V79 and SD1 cells.
;[1390..1393]:substance:"MMC"
(SENT
  (S
    (ADVP (RB:[1380..1388] Likewise))
    (,:[1388..1389] ,)
    (NP-SBJ (NN:[1390..1393] MMC))
    (VP (VBD:[1394..1397] was)
      (ADJP-PRD (JJ:[1398..1407] equitoxic))
      (PP-LOC (IN:[1408..1410] in)
        (NP
          (NP (NN:[1411..1414] V79)
            (NML-1 (-NONE-:[1414..1414] *P*)))
          (CC:[1415..1418] and)
          (NP (NN:[1419..1422] SD1)
            (NML-1 (NNS:[1423..1428] cells))))))
    (.:[1428..1429] .)))

;sentence 11 Span:1430..1505
;Co-incubation of  SD1 cells with MP did not alter MMC-induced cytotoxicity.
;[1463..1465]:substance:"MP"
;[1480..1483]:substance:"MMC"
(SENT
  (S
    (NP-SBJ
      (NP (AFX:[1430..1432] Co) (HYPH:[1432..1433] -)
          (NN:[1433..1443] incubation))
      (PP (IN:[1444..1446] of)
        (NP (NN:[1448..1451] SD1) (NNS:[1452..1457] cells)))
      (PP (IN:[1458..1462] with)
        (NP (NN:[1463..1465] MP))))
    (VP (VBD:[1466..1469] did) (RB:[1470..1473] not)
      (VP (VB:[1474..1479] alter)
        (NP
          (ADJP (NN:[1480..1483] MMC) (HYPH:[1483..1484] -)
                (VBN:[1484..1491] induced))
          (NN:[1492..1504] cytotoxicity))))
    (.:[1504..1505] .)))

;sentence 12 Span:1506..1607
;MMC, however, showed a  decreased cytotoxicity in XEM2 cells when compared to
;the parental V79 cells.
;[1506..1509]:substance:"MMC"
(SENT
  (S
    (NP-SBJ (NN:[1506..1509] MMC))
    (,:[1509..1510] ,)
    (ADVP (RB:[1511..1518] however))
    (,:[1518..1519] ,)
    (VP (VBD:[1520..1526] showed)
      (NP (DT:[1527..1528] a) (VBN:[1530..1539] decreased)
          (NN:[1540..1552] cytotoxicity))
      (PP-LOC (IN:[1553..1555] in)
        (NP (NN:[1556..1560] XEM2) (NNS:[1561..1566] cells)))
      (SBAR-ADV
        (WHADVP-1 (WRB:[1567..1571] when))
        (S
          (NP-SBJ-2 (-NONE-:[1571..1571] *))
          (VP (VBN:[1572..1580] compared)
            (NP-2 (-NONE-:[1580..1580] *))
            (PP-CLR (TO:[1581..1583] to)
              (NP (DT:[1584..1587] the) (JJ:[1588..1596] parental)
                  (NN:[1597..1600] V79) (NNS:[1601..1606] cells)))
            (ADVP-TMP-1 (-NONE-:[1606..1606] *T*))))))
    (.:[1606..1607] .)))

;sentence 13 Span:1609..1744
;Unexpectedly, the cytotoxicity of MMC in XEM2 cells was increased by alpha NF
;to  the same level as observed in the parental V79 cells.
;[1643..1646]:substance:"MMC"
;[1678..1686]:substance:"alpha NF"
(SENT
  (S
    (ADVP (RB:[1609..1621] Unexpectedly))
    (,:[1621..1622] ,)
    (NP-SBJ-1
      (NP (DT:[1623..1626] the) (NN:[1627..1639] cytotoxicity))
      (PP (IN:[1640..1642] of)
        (NP (NN:[1643..1646] MMC)))
      (PP-LOC (IN:[1647..1649] in)
        (NP (NN:[1650..1654] XEM2) (NNS:[1655..1660] cells))))
    (VP (VBD:[1661..1664] was)
      (VP (VBN:[1665..1674] increased)
        (NP-1 (-NONE-:[1674..1674] *))
        (PP (IN:[1675..1677] by)
          (NP-LGS (SYM:[1678..1683] alpha) (NN:[1684..1686] NF)))
        (PP (TO:[1687..1689] to)
          (NP
            (NP (DT:[1691..1694] the) (JJ:[1695..1699] same)
                (NN:[1700..1705] level))
            (SBAR (IN:[1706..1708] as)
              (S
                (NP-SBJ-2 (-NONE-:[1708..1708] *))
                (VP (VBN:[1709..1717] observed)
                  (NP-2 (-NONE-:[1717..1717] *))
                  (PP-LOC (IN:[1718..1720] in)
                    (NP (DT:[1721..1724] the) (JJ:[1725..1733] parental)
                        (NN:[1734..1737] V79) (NNS:[1738..1743] cells))))))))))
    (.:[1743..1744] .)))

;sentence 14 Span:1745..1943
;In contrast to V79- and  V79-derived cells, in freshly isolated hepatocytes
;from PB or beta NF-induced  rats, MMC was cytotoxic (measured as lactate
;dehydrogenase leakage) within 3 h  of incubation.
;[1826..1828]:substance:"PB"
;[1832..1839]:substance:"beta NF"
;[1855..1858]:substance:"MMC"
;[1886..1907]:substance:"lactate dehydrogenase"
;[1924..1925]:quantitative-value:"3"
;[1926..1927]:quantitative-units:"h"
(SENT
  (S
    (PP (IN:[1745..1747] In)
      (NP
        (NP (NN:[1748..1756] contrast))
        (PP (TO:[1757..1759] to)
          (NP
            (NP
              (ADJP (NN:[1760..1763] V79) (HYPH:[1763..1764] -)
                (ADJP-3 (-NONE-:[1764..1764] *P*)))
              (NML-4 (-NONE-:[1764..1764] *P*)))
            (CC:[1765..1768] and)
            (NP
              (ADJP (NN:[1770..1773] V79) (HYPH:[1773..1774] -)
                (ADJP-3 (VBN:[1774..1781] derived)))
              (NML-4 (NNS:[1782..1787] cells)))))))
    (,:[1787..1788] ,)
    (PP-LOC (IN:[1789..1791] in)
      (NP
        (NP
          (ADJP (RB:[1792..1799] freshly) (VBN:[1800..1808] isolated))
          (NNS:[1809..1820] hepatocytes))
        (PP (IN:[1821..1825] from)
          (NP
            (NP
              (ADJP (NN:[1826..1828] PB)
                (ADJP-1 (-NONE-:[1828..1828] *P*)))
              (NML-2 (-NONE-:[1828..1828] *P*)))
            (CC:[1829..1831] or)
            (NP
              (ADJP
                (NML (SYM:[1832..1836] beta) (NN:[1837..1839] NF))
                (ADJP-1 (HYPH:[1839..1840] -) (VBN:[1840..1847] induced)))
              (NML-2 (NNS:[1849..1853] rats)))))))
    (,:[1853..1854] ,)
    (NP-SBJ (NN:[1855..1858] MMC))
    (VP (VBD:[1859..1862] was)
      (ADJP-PRD (JJ:[1863..1872] cytotoxic)
        (PRN (-LRB-:[1873..1874] -LRB-)
          (VP (VBN:[1874..1882] measured)
            (NP (-NONE-:[1882..1882] *))
            (PP (IN:[1883..1885] as)
              (NP
                (NML (NN:[1886..1893] lactate) (NN:[1894..1907] dehydrogenase))
                (NN:[1908..1915] leakage))))
          (-RRB-:[1915..1916] -RRB-)))
      (PP-TMP (IN:[1917..1923] within)
        (NP
          (NP (CD:[1924..1925] 3) (NN:[1926..1927] h))
          (NP (IN:[1929..1931] of) (NN:[1932..1942] incubation)))))
    (.:[1942..1943] .)))

;sentence 15 Span:1944..2065
;ADR, however, was only cytotoxic to the hepatocytes when  intracellular
;glutathione was first depleted by diethylmaleate.
;[1944..1947]:substance:"ADR"
;[2016..2027]:substance:"glutathione"
;[2050..2064]:substance:"diethylmaleate"
(SENT
  (S
    (NP-SBJ (NN:[1944..1947] ADR))
    (,:[1947..1948] ,)
    (ADVP (RB:[1949..1956] however))
    (,:[1956..1957] ,)
    (VP (VBD:[1958..1961] was)
      (ADVP (RB:[1962..1966] only))
      (ADJP-PRD (JJ:[1967..1976] cytotoxic)
        (PP (TO:[1977..1979] to)
          (NP (DT:[1980..1983] the) (NNS:[1984..1995] hepatocytes))))
      (SBAR-ADV
        (WHADVP-2 (WRB:[1996..2000] when))
        (S
          (NP-SBJ-1 (JJ:[2002..2015] intracellular)
                    (NN:[2016..2027] glutathione))
          (VP (VBD:[2028..2031] was)
            (ADVP (RB:[2032..2037] first))
            (VP (VBN:[2038..2046] depleted)
              (NP-1 (-NONE-:[2046..2046] *))
              (PP (IN:[2047..2049] by)
                (NP-LGS (NN:[2050..2064] diethylmaleate)))
              (ADVP-2 (-NONE-:[2064..2064] *T*)))))))
    (.:[2064..2065] .)))

;sentence 16 Span:2066..2184
;The MMC- and  ADR-induced cytotoxicity was found to be more pronounced in
;PB-hepatocytes than  in beta NF-hepatocytes.
;[2070..2073]:substance:"MMC"
;[2080..2083]:substance:"ADR"
;[2140..2142]:substance:"PB"
;[2164..2171]:substance:"beta NF"
(SENT
  (S
    (NP-SBJ-3 (DT:[2066..2069] The)
      (NML
        (NML
          (ADJP (NN:[2070..2073] MMC) (HYPH:[2073..2074] -)
            (ADJP-1 (-NONE-:[2074..2074] *P*)))
          (NML-2 (-NONE-:[2074..2074] *P*)))
        (CC:[2075..2078] and)
        (NML
          (ADJP (NN:[2080..2083] ADR) (HYPH:[2083..2084] -)
            (ADJP-1 (VBN:[2084..2091] induced)))
          (NML-2 (NN:[2092..2104] cytotoxicity)))))
    (VP (VBD:[2105..2108] was)
      (VP (VBN:[2109..2114] found)
        (S
          (NP-SBJ-3 (-NONE-:[2114..2114] *))
          (VP (TO:[2115..2117] to)
            (VP (VB:[2118..2120] be)
              (ADJP-PRD
                (ADJP (RBR:[2121..2125] more) (VBN:[2126..2136] pronounced))
                (PP-4 (-NONE-:[2136..2136] *ICH*)))
              (PP-LOC (IN:[2137..2139] in)
                (NP (NN:[2140..2142] PB) (HYPH:[2142..2143] -)
                    (NNS:[2143..2154] hepatocytes)))
              (PP-4 (IN:[2155..2159] than)
                (PP-LOC (IN:[2161..2163] in)
                  (NP
                    (NML (SYM:[2164..2168] beta) (NN:[2169..2171] NF))
                    (HYPH:[2171..2172] -) (NNS:[2172..2183] hepatocytes)))))))))
    (.:[2183..2184] .)))

;sentence 17 Span:2185..2426
;Contrary to the findings in the V79-derived cells, MP  afforded complete
;protection against both MMC- and ADR-induced cytotoxicity in  PB-hepatocytes,
;whereas alpha NF only partially inhibited the cytotoxicity of  MMC in beta
;NF-hepatocytes.
;[2236..2238]:substance:"MP"
;[2282..2285]:substance:"MMC"
;[2291..2294]:substance:"ADR"
;[2320..2322]:substance:"PB"
;[2344..2352]:substance:"alpha NF"
;[2399..2402]:substance:"MMC"
;[2406..2413]:substance:"beta NF"
(SENT
  (S
    (S-ADV
      (NP-SBJ (-NONE-:[2185..2185] *))
      (ADJP-PRD (JJ:[2185..2193] Contrary)
        (PP (TO:[2194..2196] to)
          (NP
            (NP (DT:[2197..2200] the) (NNS:[2201..2209] findings))
            (PP (IN:[2210..2212] in)
              (NP (DT:[2213..2216] the)
                (ADJP (NN:[2217..2220] V79) (HYPH:[2220..2221] -)
                      (VBN:[2221..2228] derived))
                (NNS:[2229..2234] cells)))))))
    (,:[2234..2235] ,)
    (NP-SBJ (NN:[2236..2238] MP))
    (VP (VBD:[2240..2248] afforded)
      (NP
        (NP (JJ:[2249..2257] complete) (NN:[2258..2268] protection))
        (PP (IN:[2269..2276] against)
          (NP (CC:[2277..2281] both)
            (NML
              (NML
                (ADJP (NN:[2282..2285] MMC) (HYPH:[2285..2286] -)
                  (ADJP-1 (-NONE-:[2286..2286] *P*)))
                (NML-2 (-NONE-:[2286..2286] *P*)))
              (CC:[2287..2290] and)
              (NML
                (ADJP (NN:[2291..2294] ADR) (HYPH:[2294..2295] -)
                  (ADJP-1 (VBN:[2295..2302] induced)))
                (NML-2 (NN:[2303..2315] cytotoxicity)))))))
      (PP-LOC (IN:[2316..2318] in)
        (NP (NN:[2320..2322] PB) (HYPH:[2322..2323] -)
            (NNS:[2323..2334] hepatocytes)))
      (,:[2334..2335] ,)
      (SBAR-ADV (IN:[2336..2343] whereas)
        (S
          (NP-SBJ (SYM:[2344..2349] alpha) (NN:[2350..2352] NF))
          (ADVP (RB:[2353..2357] only) (RB:[2358..2367] partially))
          (VP (VBD:[2368..2377] inhibited)
            (NP
              (NP (DT:[2378..2381] the) (NN:[2382..2394] cytotoxicity))
              (PP (IN:[2395..2397] of)
                (NP (NN:[2399..2402] MMC))))
            (PP-LOC (IN:[2403..2405] in)
              (NP
                (NML (SYM:[2406..2410] beta) (NN:[2411..2413] NF))
                (HYPH:[2413..2414] -) (NNS:[2414..2425] hepatocytes)))))))
    (.:[2425..2426] .)))

;sentence 18 Span:2427..2643
;In conclusion, we have demonstrated that  PB-inducible P450s play a role in
;the cytotoxicity of both MMC and ADR in  freshly isolated PB-hepatocytes but
;that P450IIB1 does not in genetically  reconstituted SD1 cells.
;[2469..2471]:substance:"PB"
;[2482..2487]:cyp450:"P450s"
;[2528..2531]:substance:"MMC"
;[2536..2539]:substance:"ADR"
;[2561..2563]:substance:"PB"
;[2585..2593]:cyp450:"P450IIB1"
(SENT
  (S
    (PP (IN:[2427..2429] In)
      (NP (NN:[2430..2440] conclusion)))
    (,:[2440..2441] ,)
    (NP-SBJ (PRP:[2442..2444] we))
    (VP (VBP:[2445..2449] have)
      (VP (VBN:[2450..2462] demonstrated)
        (SBAR
          (SBAR (IN:[2463..2467] that)
            (S
              (NP-SBJ=1
                (ADJP (NN:[2469..2471] PB) (HYPH:[2471..2472] -)
                      (JJ:[2472..2481] inducible))
                (NNS:[2482..2487] P450s))
              (VP (VBP:[2488..2492] play)
                (NP (DT:[2493..2494] a) (NN:[2495..2499] role))
                (PP (IN:[2500..2502] in)
                  (NP
                    (NP (DT:[2503..2506] the) (NN:[2507..2519] cytotoxicity))
                    (PP (IN:[2520..2522] of)
                      (NP (CC:[2523..2527] both)
                        (NML (NN:[2528..2531] MMC) (CC:[2532..2535] and)
                             (NN:[2536..2539] ADR))))))
                (PP-LOC=2 (IN:[2540..2542] in)
                  (NP
                    (ADJP (RB:[2544..2551] freshly) (VBN:[2552..2560] isolated))
                    (NN:[2561..2563] PB) (HYPH:[2563..2564] -)
                     (NNS:[2564..2575] hepatocytes))))))
          (CC:[2576..2579] but)
          (SBAR (IN:[2580..2584] that)
            (S
              (NP-SBJ=1 (NN:[2585..2593] P450IIB1))
              (VP (VBZ:[2594..2598] does) (RB:[2599..2602] not)
                (PP-LOC=2 (IN:[2603..2605] in)
                  (NP
                    (ADJP (RB:[2606..2617] genetically)
                          (VBN:[2619..2632] reconstituted))
                    (NN:[2633..2636] SD1) (NNS:[2637..2642] cells)))))))))
    (.:[2642..2643] .)))

;sentence 19 Span:2644..2715
;P450IA1, however, decreased the cytotoxicity of MMC in  the XEM2 cells.
;[2644..2651]:cyp450:"P450IA1"
;[2692..2695]:substance:"MMC"
(SENT
  (S
    (NP-SBJ (NN:[2644..2651] P450IA1))
    (,:[2651..2652] ,)
    (ADVP (RB:[2653..2660] however))
    (,:[2660..2661] ,)
    (VP (VBD:[2662..2671] decreased)
      (NP
        (NP (DT:[2672..2675] the) (NN:[2676..2688] cytotoxicity))
        (PP (IN:[2689..2691] of)
          (NP (NN:[2692..2695] MMC))))
      (PP-LOC (IN:[2696..2698] in)
        (NP (DT:[2700..2703] the) (NN:[2704..2708] XEM2)
            (NNS:[2709..2714] cells))))
    (.:[2714..2715] .)))

;sentence 20 Span:2716..2809
;The ADR-induced cytotoxicity, which was observed in XEM2 cells,  was not
;mediated by P450IA1.
;[2720..2723]:substance:"ADR"
;[2801..2808]:cyp450:"P450IA1"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[2716..2719] The)
        (ADJP (NN:[2720..2723] ADR) (HYPH:[2723..2724] -)
              (VBN:[2724..2731] induced))
        (NN:[2732..2744] cytotoxicity))
      (,:[2744..2745] ,)
      (SBAR
        (WHNP-1 (WDT:[2746..2751] which))
        (S
          (NP-SBJ-1 (-NONE-:[2751..2751] *T*))
          (VP (VBD:[2752..2755] was)
            (VP (VBN:[2756..2764] observed)
              (NP-1 (-NONE-:[2764..2764] *))
              (PP-LOC (IN:[2765..2767] in)
                (NP (NN:[2768..2772] XEM2) (NNS:[2773..2778] cells))))))))
    (,:[2778..2779] ,)
    (VP (VBD:[2781..2784] was) (RB:[2785..2788] not)
      (VP (VBN:[2789..2797] mediated)
        (NP-2 (-NONE-:[2797..2797] *))
        (PP (IN:[2798..2800] by)
          (NP-LGS (NN:[2801..2808] P450IA1)))))
    (.:[2808..2809] .)))

;sentence 21 Span:2810..2939
;The present study underscores the complexity in the  comparison of ADR- and
;MMC-induced cytotoxicities in normal and tumor cells.
;[2877..2880]:substance:"ADR"
;[2886..2889]:substance:"MMC"
(SENT
  (S
    (NP-SBJ (DT:[2810..2813] The) (JJ:[2814..2821] present)
            (NN:[2822..2827] study))
    (VP (VBZ:[2828..2839] underscores)
      (NP
        (NP (DT:[2840..2843] the) (NN:[2844..2854] complexity))
        (PP (IN:[2855..2857] in)
          (NP
            (NP (DT:[2858..2861] the) (NN:[2863..2873] comparison))
            (PP (IN:[2874..2876] of)
              (NP
                (NP
                  (ADJP (NN:[2877..2880] ADR) (HYPH:[2880..2881] -)
                    (ADJP-2 (-NONE-:[2881..2881] *P*)))
                  (NML-3 (-NONE-:[2881..2881] *P*)))
                (CC:[2882..2885] and)
                (NP
                  (ADJP (NN:[2886..2889] MMC) (HYPH:[2889..2890] -)
                    (ADJP-2 (VBN:[2890..2897] induced)))
                  (NML-3 (NNS:[2898..2912] cytotoxicities)))))
            (PP-LOC (IN:[2913..2915] in)
              (NP
                (NP (JJ:[2916..2922] normal)
                  (NML-1 (-NONE-:[2922..2922] *P*)))
                (CC:[2923..2926] and)
                (NP (NN:[2927..2932] tumor)
                  (NML-1 (NNS:[2933..2938] cells)))))))))
    (.:[2938..2939] .)))

;section 22 Span:2943..2987
;PMID: 7606813 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2943..2947] PMID) (::[2947..2948] :) (CD:[2949..2956] 7606813)
        (NN:[2957..2958] -LSB-) (NNP:[2958..2964] PubMed) (::[2965..2966] -)
        (NN:[2967..2974] indexed) (IN:[2975..2978] for)
        (NNP:[2979..2987] MEDLINE-RSB-)))
